Margherita Ambrosini, Medical Doctor, Oncology Clinical and Research Fellow at the Fondazione IRCCS National Cancer Institute in Milan, shared a post on LinkedIn:
“In this review, we delve into the key features of MSI-H/dMMR cancers, shedding light on current diagnostic challenges and the impact of immune checkpoint inhibitors across both advanced and early-stage disease.
Have a look.”
“Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers”
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio
